NCT07840326

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

Recruiting · Phase 2 · Sundance Biosciences, Inc. · registry updated 2026-10-30

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.

Inclusion

Aged 18-70, inclusive
Diagnosis of PPMS or non-active SPMS
No MS relapses in the past 2 years
Evidence that MS has continued to get worse over time
A level of disability that fits the study requirements

Exclusion

Use of certain medications or treatments before the study, or need for these treatments during the study
Current participation in another research study
Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk
Certain serious or unstable medical conditions that could make the study unsafe
Active infection, recent infection, or a history of repeated infections
Additional inclusion and exclusion criteria are outlined in the full study protocol.

Open NCT07840326 on ClinicalTrials.gov All conditions